Unlock instant, AI-driven research and patent intelligence for your innovation.

Dihydroisoquinoline-3-formyl-LARGD(aa)aa as well as preparation, phlebothrombosis resisting activity and application thereof

A technology of dihydroisoquinoline and venous thrombosis, which is applied in the field of biomedicine and can solve the problems of no therapeutic effect, bleeding, and little effect on venous thrombosis

Active Publication Date: 2019-05-28
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although warfarin has been used clinically since 1941, its safety window is narrow
Low doses can cause pulmonary embolism, high doses can cause fatal bleeding
Over the past 50 years, although a lot of effort has been devoted to the invention of safe anti-venous thrombosis drugs, the results have been minimal
In antithrombotic drug research, the inventor once disclosed that intravenous injection of N-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-formyl]-Leu-Arg- Gly-Asp(Ser)-Ser,N-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-formyl]-Leu-Arg-Gly-Asp(Val)-Val and N -[(3S)-1,2,3,4-Tetrahydroisoquinoline-3-formyl]-Leu-Arg-Gly-Asp(Phe)-Phe can effectively inhibit rat arterial thrombosis, and has no effect on venous thrombosis Therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dihydroisoquinoline-3-formyl-LARGD(aa)aa as well as preparation, phlebothrombosis resisting activity and application thereof
  • Dihydroisoquinoline-3-formyl-LARGD(aa)aa as well as preparation, phlebothrombosis resisting activity and application thereof
  • Dihydroisoquinoline-3-formyl-LARGD(aa)aa as well as preparation, phlebothrombosis resisting activity and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 Preparation of N-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-formyl]-Leu-Ala-Arg-Gly-Asp(aa)-aa

[0014] Prepare N-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-formyl]-Leu-Ala-Arg-Gly-Asp(aa)-aa (wherein aa is a Ser, Val or Phe residue).

Embodiment 2

[0015] Example 2 Preparation of 1,2-dihydroisoquinoline-3-formyl-Leu-Ala-Arg-Gly-Asp-(Ser)-Ser(10a)

[0016] 50mg (0.04mmol) N-[(3S)-N-1,2,3,4-tetrahydroisoquinoline-3-formyl]-Leu-Ala-Arg-Gly-Asp(Ser)-Ser in Dissolve with 1mL mouse serum at 37°C, shake the obtained solution at a constant temperature of 37°C for 4 hours, and monitor the disappearance of raw materials by TLC. Add 2 mL of methanol to the serum solution and shake at a constant temperature of 37°C for 10 minutes, and the resulting mixed solution is centrifuged at 3000 rpm for 10 minutes. The residue obtained by centrifugation was fully extracted with ultrapure water, and the extract was separated and centrifuged. The supernatant obtained by centrifugation was concentrated under reduced pressure at 37°C, the residue was fully extracted with ultrapure water, and the extract was separated. The combined extracts were lyophilized to yield 33 mg (96%) of the title compound. ESI(+)-FT-MS:862.50597[M+H] + .Mp 134-135℃....

Embodiment 3

[0017] Example 3 Preparation of 1,2-dihydroisoquinoline-3-formyl-Leu-Ala-Arg-Gly-Asp(Val)-Val(10b)

[0018] According to the method of Example 1, by 50mg (0.04mmol) N-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-formyl]-Leu-Ala-Arg-Gly-Asp(Val )-Val yielded 33 mg (96%) of the title compound. ESI(-)-FT-MS:884.47145[M-H] - .Mp 162-163℃.[α] D 25 =-14.2 (c=1.6, CH 3 OH).IR(cm -1 )3448,3250,2965,2383,1656,1544,1458,1392,1250,1170,1027,765,643,514,439. 1 H NMR (300MHz, DMSO) δ / ppm=11.02(s,2H),8.56(s,1H),8.55(s,1H),8.04(m,7H),7.50(d,J=7.5Hz,1H) ,7.24(m,J=5.5Hz,2H),7.15(d,J=8Hz,1H),6.66(s,1H),4.38(d,J=3.9Hz,1H),4.37-4.26(m,3H ),3.21-3.11(m,2H),2.80(d,J=4.8Hz,1H),2.14-2.03(m,2H),1.92-1.77(m,3H),1.67-1.53(m,5H), 1.35 (d, J = 2.1 Hz, 3H), 0.91-0.76 (m, 18H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses 1,2-dihydroisoquinoline-3-formyl-Leu-Ala-Arg-Gly-Asp(aa)-aa shown as a formula. In the formula, aa is Phe, Ser or Val residue. The invention further discloses a preparation method, the phlebothrombosis resisting activity and application of 1,2-dihydroisoquinoline-3-formyl-Leu-Ala-Arg-Gly-Asp(aa)-aa to the preparation of a phlebothrombosis resistant medicament. The formula is shown in the description.

Description

technical field [0001] The present invention relates to 1,2-dihydroisoquinoline-3-formyl-Leu-Ala-Arg-Gly-Asp(aa)-aa, to their preparation methods, to their anti-venous thrombosis activity, and thus the present invention It relates to their application in the preparation of anti-venous thrombosis drugs. The invention belongs to the field of biomedicine. Background technique [0002] Thrombosis has become a disease with high morbidity and mortality. The number of patients with venous thrombosis, including deep vein thrombosis and pulmonary embolism, exceeds the total incidence of myocardial infarction and stroke, and is higher than the total number of deaths caused by breast cancer and AIDS. The incidence of thrombosis increases exponentially with age, which poses a serious threat to people's health in aging countries like my country. If included in the population base, the negative impact of venous thrombosis on my country's national economy and people's livelihood is part...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61P7/02
Inventor 赵明彭师奇桂琳张筱宜
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES